Subcutaneous Implantable Cardioverter-Defibrillator Therapy in Women
JACC: Clinical Electrophysiology · 2026-08
DOI: 10.1016/j.jacep.2026.06.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2026-08. Verfasst von Rodrigue Garcia und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Hospital of Poitiers, Poitiers, France; Centre d'Investigation Clinique 1402, University Hospital of Poitiers, P…. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) is an established therapy for sudden cardiac death prevention, but sex-specific outcomes remain incompletely characterized. OBJECTIVES: This study evaluated sex-related differences in baseline characteristics, appropriate shocks, complications, reinterventions, and mortality among S-ICD recipients. METHODS: The nationwide HONEST (S-ICD French Cohort Study) cohort enrolled all patients who received an S-ICD in France between 2012 and 2019. Clinical endpoints were centrally adjudicated. Sex-specific associations with outcomes were assessed by using propensity score-based inverse probability weighting. RESULTS: Among 4,924 S-ICD recipients, 1,148 were women (23.3%). Compared with men, women were younger (47.3 ± 15.6 years vs 50.6 ± 14.7 years; P < 0.001), less frequently received an implant for primary prevention (57.6% vs 65.1%; P < 0.001), less often had coronary artery disease (38.9% vs 56.5%; P < 0.001), and more often had electrical heart disease (26.3% vs 20.4%; P < 0.001). After adjustment, women had a lower 5-year risk of appropriate shocks (HR: 0.85; 95% CI: 0.74-0.98; P = 0.023) and similar overall complication and reintervention rates but a distinct complication profile, with higher risks of chronic pain (HR: 2.63; 95% CI: 1.61-4.29; P < 0.001) and lead dislodgment (HR: 1.79; 95% CI: 1.09-2.95; P = 0.022) and a lower risk of inappropriate shocks (HR: 0.64; 95% CI: 0.50-0.82; P < 0.001). All-cause mortality was lower in women, whereas S-ICD-unresponsive sudden death and device-related mortality were similar. CONCLUSIONS: Women receiving an S-ICD experienced fewer appropriate shocks, with similar overall complication and reintervention rates, but a distinct complication profile. These findings support sex-informed S-ICD selection and follow-up. (S-ICD French Cohort Study [HONEST]; NCT05302115).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, University Hospital of Poitiers, Poitiers, France; Centre d'Investigation Clinique 1402, University Hospital of Poitiers, Poitiers, France.
- Department of Cardiology, University Hospital of Brest, Brest, France; Division of Cardiology, European Georges Pompidou Hospital, Paris, France; Université Paris Cité, INSERM U970, Paris Cardiovascular Research Centre,…
- Heart and Lung Institute, University Hospital of Lille, Lille, France.
- Department of Cardiology, Hôpital Privé Jacques Cartier, Massy, France.
- Department of Cardiology, University Hospital of Rouen, Rouen, France.
- Division of Cardiology, European Georges Pompidou Hospital, Paris, France; Université Paris Cité, INSERM U970, Paris Cardiovascular Research Centre, Paris, France.
Zitieren
APA
Garcia, R., Kerkouri, F., Marquié, C., Ait Said, M., Anselme, F., Aoudjeghout, W., Badenco, N., Badoz, M., Barra, S., Barthez, O., Blangy, H., Bordachar, P., Champ-Rigot, L., Combes, S., Defaye, P., Deharo, J. C., Gandjbakhch, E., Gitenay, E., Gorka, H., …, & HONEST Investigators (2026). Subcutaneous Implantable Cardioverter-Defibrillator Therapy in Women. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2026.06.013
Vancouver
Garcia R, Kerkouri F, Marquié C, Ait Said M, Anselme F, Aoudjeghout W, et al. Subcutaneous Implantable Cardioverter-Defibrillator Therapy in Women. JACC: Clinical Electrophysiology. 2026. doi:10.1016/j.jacep.2026.06.013
BibTeX
@article{Garcia2026,
author = {Garcia, Rodrigue and Kerkouri, Fawzi and Marquié, Christelle and Ait Said, Mina and Anselme, Frédéric and Aoudjeghout, Warda and Badenco, Nicolas and Badoz, Marc and Barra, Sergio and Barthez, Olivier and Blangy, Hugues and Bordachar, Pierre and Champ-Rigot, Laure and Combes, Stéphane and Defaye, Pascal and Deharo, Jean Claude and Gandjbakhch, Estelle and Gitenay, Edouard and Gorka, Hervé and Heurtebise, Isabelle and Hourdain, Jérôme and Jesel, Laurence and Khris, Lila and Lebon, Alain and Leclercq, Christophe and Le Page, Sophie and Mechulan, Alexis and Mondoly, Pierre and Pasquié, Jean-Luc and Perrot, David and Pierre, Bertrand and Piot, Olivier and Quentin, Anne and Rendu, Eric and Villejoubert, Olivier and Waldmann, Victor and Weizman, Orianne and Probst, Vincent and Boveda, Serge and Marijon, Eloi and HONEST Investigators, HONEST Investigators},
title = {Subcutaneous Implantable Cardioverter-Defibrillator Therapy in Women},
journal = {JACC: Clinical Electrophysiology},
year = {2026},
doi = {10.1016/j.jacep.2026.06.013}
}
EUVIMED